Log in
NYSE:MED

Medifast Stock Forecast, Price & News

$150.56
+3.32 (+2.25 %)
(As of 10/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$148.68
Now: $150.56
$151.67
50-Day Range
$146.12
MA: $165.39
$179.37
52-Week Range
$49.03
Now: $150.56
$184.29
Volume78,711 shs
Average Volume269,131 shs
Market Capitalization$1.77 billion
P/E Ratio23.53
Dividend Yield3.07%
Beta1.18
Medifast, Inc., through its subsidiaries, manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products. It offers bars, bites, pretzels, puffs, oatmeal and cereal crunch products, drinks, hearty choices, pancakes, puddings, soft serves, shakes, smoothies, soft bakes, and soups under the Medifast, OPTAVIA, Thrive by Medifast, Optimal Health by OPTAVIA, Flavors of Home, and Essential 1 brands. The company sells its products through various channels, including the Internet, call centers, independent health advisors, franchise weight loss clinics, and direct consumer marketing. The company was founded in 1980 and is headquartered in Baltimore, Maryland.
Read More
Medifast logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.4Dividend Strength: 1.7Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.71 out of 5 stars

Industry, Sector and Symbol

Industry Miscellaneous food preparations & kindred products
Sub-IndustryPersonal Products
CUSIP58470H10
Phone410-581-8042
Employees420

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$713.67 million
Cash Flow$6.57 per share
Book Value$9.03 per share

Profitability

Net Income$77.92 million

Miscellaneous

Market Cap$1.77 billion
Next Earnings Date11/5/2020 (Estimated)
OptionableOptionable
$150.56
+3.32 (+2.25 %)
(As of 10/23/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MED News and Ratings via Email

Sign-up to receive the latest news and ratings for MED and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Medifast (NYSE:MED) Frequently Asked Questions

How has Medifast's stock been impacted by Coronavirus (COVID-19)?

Medifast's stock was trading at $70.44 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, MED stock has increased by 113.7% and is now trading at $150.56.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Medifast?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medifast in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Medifast
.

When is Medifast's next earnings date?

Medifast is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Medifast
.

How were Medifast's earnings last quarter?

Medifast Inc (NYSE:MED) announced its quarterly earnings results on Wednesday, August, 5th. The specialty retailer reported $1.96 EPS for the quarter, beating the Zacks' consensus estimate of $1.84 by $0.12. The specialty retailer had revenue of $220 million for the quarter, compared to the consensus estimate of $194.75 million. Medifast had a net margin of 10.04% and a return on equity of 68.55%.
View Medifast's earnings history
.

How often does Medifast pay dividends? What is the dividend yield for Medifast?

Medifast declared a quarterly dividend on Thursday, September 10th. Investors of record on Tuesday, September 22nd will be given a dividend of $1.13 per share on Friday, November 6th. This represents a $4.52 annualized dividend and a yield of 3.00%. The ex-dividend date is Monday, September 21st.
View Medifast's dividend history
.

What price target have analysts set for MED?

4 Wall Street analysts have issued 1 year price targets for Medifast's stock. Their forecasts range from $180.00 to $230.00. On average, they anticipate Medifast's stock price to reach $206.67 in the next year. This suggests a possible upside of 37.3% from the stock's current price.
View analysts' price targets for Medifast
.

Who are some of Medifast's key competitors?

What other stocks do shareholders of Medifast own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medifast investors own include NVIDIA (NVDA), Alibaba Group (BABA), AbbVie (ABBV), Home Depot (HD), The Boeing (BA), Johnson & Johnson (JNJ), Intel (INTC), Cisco Systems (CSCO), AT&T (T) and Exxon Mobil (XOM).

Who are Medifast's key executives?

Medifast's management team includes the following people:
  • Mr. Daniel R. Chard, CEO & Director (Age 54)
  • Mr. Timothy G. Robinson CPA, CPA, Chief Financial Officer (Age 57)
  • Mr. William Baker IV, Exec. VP of Information Technology (Age 47)
  • Mr. Nicholas Johnson, Exec. VP of Coach Success Market Pres of OPTAVIA USA (Age 39)
  • Mr. Jason L. Groves, Exec. VP, Gen. Counsel & Corp. Sec. (Age 48)

What is Medifast's stock symbol?

Medifast trades on the New York Stock Exchange (NYSE) under the ticker symbol "MED."

Who are Medifast's major shareholders?

Medifast's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Ingalls & Snyder LLC (0.42%), Chickasaw Capital Management LLC (0.26%), State of Alaska Department of Revenue (0.09%), Campbell Newman Asset Management Inc. (0.07%), Louisiana State Employees Retirement System (0.05%) and Avantax Advisory Services Inc. (0.04%). Company insiders that own Medifast stock include Carl E Sassano, Constance J Hallquist, Daniel R Chard, Jeffrey J Brown, Michael A Hoer, Michael C Macdonald and Scott Schlackman.
View institutional ownership trends for Medifast
.

Which institutional investors are selling Medifast stock?

MED stock was sold by a variety of institutional investors in the last quarter, including First Midwest Bank Trust Division, Ingalls & Snyder LLC, Envestnet Asset Management Inc., Carroll Financial Associates Inc., First Citizens Bank & Trust Co., Crossmark Global Holdings Inc., FormulaFolio Investments LLC, and State of Alaska Department of Revenue. Company insiders that have sold Medifast company stock in the last year include Michael C Macdonald, and Scott Schlackman.
View insider buying and selling activity for Medifast
.

Which institutional investors are buying Medifast stock?

MED stock was bought by a variety of institutional investors in the last quarter, including Campbell & CO Investment Adviser LLC, Louisiana State Employees Retirement System, Bowling Portfolio Management LLC, Nisa Investment Advisors LLC, Avantax Advisory Services Inc., Campbell Newman Asset Management Inc., Spearhead Capital Advisors LLC, and Chickasaw Capital Management LLC. Company insiders that have bought Medifast stock in the last two years include Daniel R Chard, Jeffrey J Brown, and Michael A Hoer.
View insider buying and selling activity for Medifast
.

How do I buy shares of Medifast?

Shares of MED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Medifast's stock price today?

One share of MED stock can currently be purchased for approximately $150.56.

How big of a company is Medifast?

Medifast has a market capitalization of $1.77 billion and generates $713.67 million in revenue each year. The specialty retailer earns $77.92 million in net income (profit) each year or $5.96 on an earnings per share basis. Medifast employs 420 workers across the globe.

What is Medifast's official website?

The official website for Medifast is www.medifast1.com.

How can I contact Medifast?

Medifast's mailing address is 100 International Drive, Baltimore MD, 21202. The specialty retailer can be reached via phone at 410-581-8042 or via email at [email protected]

This page was last updated on 10/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.